Overactive Bladder

OAB drugs draw flak for allegedly weak efficacy


An FDA advisory panel endorsed Astellas' overactive bladder medication mirabegron April 6, but not everyone is on board.

DDR on DTC: Toviaz vs. Vesicare

DDR on DTC: Toviaz vs. Vesicare

Two brands are fighting for attention from OAB sufferers: GSK-Astellas's Vesicare and Pfizer's Toviaz. Their DTC approaches couldn't be more different.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.